Amicus Therapeutics/FOLD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Amicus Therapeutics

Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

Ticker

FOLD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bradley Campbell

Employees

517

Headquarters

Philadelphia, United States

FOLD Metrics

BasicAdvanced
$2.9B
Market cap
-
P/E ratio
-$0.49
EPS
0.73
Beta
-
Dividend rate
$2.9B
0.73318
$14.57
$9.02
2.8M
3.035
2.607
297.176
297.176
-1.36%
-20.68%
-126.10%
-25.76%
6.854
22.207
25.74%
29.82%
15.25%

What the Analysts think about FOLD

Analyst Ratings

Majority rating from 12 analysts.
Buy

FOLD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-43.84% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$110M
-4.00%
Net income
-$48M
43.20%
Profit margin
-43.84%
49.17%

FOLD Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 144.07%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.15
-$0.07
-$0.11
-$0.16
-
Expected
-$0.12
-$0.08
-$0.06
-$0.07
-$0.05
Surprise
21.62%
-7.35%
86.79%
144.07%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Amicus Therapeutics stock?

Amicus Therapeutics (FOLD) has a market cap of $2.9B as of June 14, 2024.

What is the P/E ratio for Amicus Therapeutics stock?

The price to earnings (P/E) ratio for Amicus Therapeutics (FOLD) stock is 0 as of June 14, 2024.

Does Amicus Therapeutics stock pay dividends?

No, Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders as of June 14, 2024.

When is the next Amicus Therapeutics dividend payment date?

Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders.

What is the beta indicator for Amicus Therapeutics?

Amicus Therapeutics (FOLD) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Amicus Therapeutics stock price target?

The target price for Amicus Therapeutics (FOLD) stock is $17.4, which is NaN% below the current price of $. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Amicus Therapeutics stock

Buy or sell Amicus Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing